Follistatin attenuates early liver fibrosis: Effects on hepatic stellate cell activation and hepatocyte apoptosis

American Journal of Physiology - Gastrointestinal and Liver Physiology

Volumn 290, Issue 1, 2006, Pages

  Patella, Shane ^a   Phillips, David J ^b   Tchongue, Jorge ^a   De Kretser, David M ^b   Sievert, William ^a,c  

^a HUDSON INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c MONASH MEDICAL CENTRE   (Australia)

Author keywords

Activin; Cirrhosis; Hepatocytes

Indexed keywords

ACTIVIN; ACTIVIN A; CALCIUM CHLORIDE; FOLLISTATIN; MESSENGER RNA; RECOMBINANT HUMAN FOLLISTATIN 288; RECOMBINANT PROTEIN; SMOOTH MUSCLE ACTIN; UNCLASSIFIED DRUG; INHIBIN; PROTEIN SUBUNIT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL ACTIVATION; CELL CULTURE; CELL PROLIFERATION; CONTROLLED STUDY; FIBROGENESIS; GENE EXPRESSION; LIVER CELL; LIVER CIRRHOSIS; LIVER FIBROSIS; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; STELLATE CELL; UPREGULATION; ANIMAL; CYTOLOGY; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; PROTEIN TRANSPORT; TIME; WISTAR RAT;

ACTIVINS; ANIMALS; APOPTOSIS; FOLLISTATIN; GENE EXPRESSION REGULATION; HEPATOCYTES; INHIBIN-BETA SUBUNITS; LIVER CIRRHOSIS; MALE; PROTEIN SUBUNITS; PROTEIN TRANSPORT; RATS; RATS, WISTAR; RNA, MESSENGER; TIME FACTORS; UP-REGULATION;

EID: 33644803768     PISSN: 01931857     EISSN: 15221547     Source Type: Journal    
DOI: 10.1152/ajpgi.00080.2005     Document Type: Article

References (39)

1. Alcolado R, Arthur MJ, and Iredale JP. Pathogenesis of liver fibrosis. Clin Sci (Lond) 92: 103-112, 1997.
2. Canbay A, Friedman S, and Gores GJ. Apoptosis: the nexus of liver injury and fibrosis. Hepatology 39: 273-278, 2004.
3. Cooper JA Jr. Pulmonary fibrosis: pathways are slowly coming into light. Am J Respir Cell Mol Biol 22: 520-523, 2000.
4. Date M, Matsuzaki K, Matsushita M, Tahashi Y, Sakitani K, and Inoue K. Differential regulation of activin A for hepatocyte growth and fibronectin synthesis in rat liver injury. J Hepatol 32: 251-260, 2000.
5. De Bleser PJ, Niki T, Xu G, Rogiers V, and Geerts A. Localization and cellular sources of activins in normal and fibrotic rat liver. Hepatology 26: 905-912, 1997.
6. Dohi T, Ejima C, Kato R, Kawamura YI, Kawashima R, Mizutani N, Tabuchi Y, and Kojima I. Therapeutic potential of follistatin for colonic inflammation in mice. Gastroenterology 128: 411-423, 2005.
7. Friedman SL. Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J Biol Chem 275: 2247-2250, 2000.
8. Gaedeke J, Peters H, Noble NA, and Border WA. Angiotensin II, TGF-beta and renal fibrosis. Contrib Nephrol: 153-160, 2001.
9. Geerts A, Niki T, Hellemans K, De Craemer D, Van Den Berg K, Lazou JM, Stange G, Van De Winkel M, and De Bleser P. Purification of rat hepatic stellate cells by side scatter-activated cell sorting. Hepatology 27: 590-598, 1998.
10. George J, Roulot D, Koteliansky VE, and Bissell DM. In vivo inhibition of rat stellate cell activation by soluble transforming growth factor beta type II receptor: a potential new therapy for hepatic fibrosis. Proc Natl Acad Sci USA 96: 12719-12724, 1999.
11. Gressner AM, Weiskirchen R, Breitkopf K, and Dooley S. Roles of TGF-beta in hepatic fibrosis. Front Biosci 7: d793-d807, 2002.
12. Hully JR, Chang L, Schwall RH, Widmer HR, Terrell TG, and Gillett NA. Induction of apoptosis in the murine liver with recombinant human activin A. Hepatology 20: 854-862, 1994.
13. Ichikawa T, Zhang YQ, Kogure K, Hasegawa Y, Takagi H, Mori M, and Kojima I. Transforming growth factor beta and activin tonically inhibit DNA synthesis in the rat liver. Hepatology 34: 918-925, 2001.
14. Inagaki Y, Kushida M, Higashi K, Itoh J, Higashiyama R, Hong YY, Kawada N, Namikawa K, Kiyama H, Bou-Gharios G, Watanabe T, Okazaki I, and Ikeda K. Cell type-specific intervention of transforming growth factor beta/Smad signaling suppresses collagen gene expression and hepatic fibrosis in mice. Gastroenterology 129: 259-268, 2005.
15. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, Denk H, Desmet V, Korb G, MacSween RN, Phillips MJ, Portman BG, Poulsen H, Schever PJ, Schmid M, and Thaler H. Histological grading and staging of chronic hepatitis. J Hepatol 22: 696-699, 1995.
16. Jamall IS, Finelli VN, and Que Hee SS. A simple method to determine nanogram levels of 4-hydroxyproline in biological tissues. Anal Biochem 112: 70-75, 1981.
17. Jarred RA, Cancilla B, Richards M, Groome NP, McNatty KP, and Risbridger GP. Differential localization of inhibin subunit proteins in the ovine testis during fetal gonadal development. Endocrinology 140: 979-986, 1999.
18. Knight PG, Muttukrishna S, and Groome NP. Development and application of a two-site enzyme immunoassay for the determination of "total" activin-A concentrations in serum and follicular fluid. J Endocrinol 148: 267-279, 1996.
19. Kogure K, Omata W, Kanzaki M, Zhang YQ, Yasuda H, Mine T, and Kojima I. A single intraportal administration of follistatin accelerates liver regeneration in partially hepatectomized rats. Gastroenterology 108: 1136-1142, 1995.
20. Kogure K, Zhang YQ, Kanzaki M, Omata W, Mine T, and Kojima I. Intravenous administration of follistatin: delivery to the liver and effect on liver regeneration after partial hepatectomy. Hepatology 24: 361-366, 1996.
21. Kogure K, Zhang YQ, Maeshima A, Suzuki K, Kuwano H, and Kojima I. The role of activin and transforming growth factor-beta in the regulation of organ mass in the rat liver. Hepatology 31: 916-921, 2000.
22. Koseki T, Yamato K, Ishisaki A, Hashimoto O, Sugino H, and Nishihara T. Correlation between Bcl-X expression and B-cell hybridoma apoptosis induced by activin A. Cell Signal 10: 517-521, 1998.
23. McPherson SJ, Mellor SL, Wang H, Evans LW, Groome NP, and Risbridger GP. Expression of activin A and follistatin core proteins by human prostate tumor cell lines. Endocrinology 140: 5303-5309, 1999.
24. Mellor SL, Cranfield M, Ries R, Pedersen J, Cancilla B, de Kretser D, Groome NP, Mason AJ, and Risbridger GP. Localization of activin beta(A)-, beta(B)-, and beta(C)-subunits in humanprostate and evidence for formation of new activin heterodimers of beta(C)-subunit. J Clin Endocrinol Metab 85: 4851-4858, 2000.
25. Patella S, Phillips DJ, de Kretser DM, Evans LW, Groome NP, and Sievert W. Characterization of serum activin-A and follistatin and their relation to virological and histological determinants in chronic viral hepatitis. J Hepatol 34: 576-583, 2001.
26. Peters H, Noble NA, and Border WA. Transforming growth factor-beta in human glomerular injury. Curr Opin Nephrol Hypertens 6: 389-393, 1997.
27. Phillips DJ and de Kretser DM. Follistatin: a multifunctional regulatory protein. Front Neuroendocrinol 19: 287-322, 1998.
28. Phillips DJ, Jones KL, Scheerlinck JY, Hedger MP, and de Kretser DM. Evidence for activin A and follistatin involvement in the systemic inflammatory response. Mol Cell Endocrinol 180: 155-162, 2001.
29. Qi Z, Atsuchi N, Ooshima A, Takeshita A, and Ueno H. Blockade of type beta transforming growth factor signaling prevents liver fibrosis and dysfunction in the rat. Proc Natl Acad Sci USA 96: 2345-2349, 1999.
30. Ramm GA. Isolation and culture of rat hepatic stellate cells. J Gastroenterol Hepatol 13: 846-851, 1998.
31. Reeves HL and Friedman SL. Activation of hepatic stellate cells-a key issue in liver fibrosis. Front Biosci 7: d808-d826, 2002.
32. Schneyer AL, Rzucidlo DA, Sluss PM, and Crowley WF Jr. Characterization of unique binding kinetics of follistatin and activin or inhibin in serum. Endocrinology 135: 667-674, 1994.
33. Schwall RH, Robbins K, Jardieu P, Chang L, Lai C, and Terrell TG. Activin induces cell death in hepatocytes in vivo and in vitro. Hepatology 18: 347-356, 1993.
34. Sugiyama M, Ichida T, Sato T, Ishikawa T, Matsuda Y, and Asakura H. Expression of activin A is increased in cirrhotic and fibrotic rat livers. Gastroenterology 114: 550-558, 1998.
35. Takehara T, Tatsumi T, Suzuki T, Rucker EB, 3rd Hennighausen L, Jinushi M, Miyagi T, Kanazawa Y, and Hayashi N. Hepatocyte-specific disruption of Bcl-xL leads to continuous hepatocyte apoptosis and liver fibrotic responses. Gastroenterology 127: 1189-1197, 2004.
36. Wada W, Kuwano H, Hasegawa Y, and Kojima I. The dependence of transforming growth factor-beta-induced collagen production on autocrine factor activin A in hepatic stellate cells. Endocrinology 145: 2753-2759, 2004.
37. Welt C, Sidis Y, Keutmann H, and Schneyer A. Activins, inhibins, and follistatins: from endocrinology to signaling. A paradigm for the new millennium. Exp Biol Med (Maywood) 227: 724-752, 2002.
38. Williams EJ, Benyon RC, Trim N, Hadwin R, Grove BH, Arthur MJ, Unemori EN, and Iredale JP. Relaxin inhibits effective collagen deposition by cultured hepatic stellate cells and decreases rat liver fibrosis in vivo. Gut 49: 577-583, 2001.
39. Yasuda H, Mine T, Shibata H, Eto Y, Hasegawa Y, Takeuchi T, Asano S, and Kojima I. Activin A: an autocrine inhibitor of initiation of DNA synthesis in rat hepatocytes. J Clin Invest 92: 1491-1496, 1993.